YOU’RE INVITED!

Immediately following the afternoon session on Saturday, May 4, there will be a networking and socializing reception co-sponsored by the SUO and Young Urologic Oncologists (Y.U.O.). The reception will be held in W196 ABC Foyer. Seasoned urologic oncologists, as well as residents, fellows and medical students are welcome to attend.

**SUO/Y.U.O. RECEPTION**
McCormick Place | W196 ABC Foyer
5:00 p.m. – 6:00 p.m.
Business Attire

---

**2019 SUO Award Winners**

**WHITMORE LECTURER:**
**Joseph Smith, MD**

The Willet F. Whitmore Jr. Lectureship was established in 1993 as a keynote address to be delivered at the Annual Meeting and as a tribute to Dr. Whitmore, who embodied the field of urologic oncology as a premier urologic surgeon and as a pioneer in the multidisciplinary aspects of urologic care.

**SUO MEDAL:**
**J. Brantley Thrasher, MD, FACS**

Awarded to an individual for a specific achievement and/or significant contributions in the field of urologic oncology.

**YOUNG INVESTIGATOR AWARD:**
**Brian Chapin, MD**

Recognition by the Society of excellence for a singular contribution or consistent pattern of performance in clinical practice and/or basic research that has contributed to improvement of clinical care and progress in science. Awarded to a urologist who is within 10 years of completion of residency or fellowship.

**DISTINGUISHED SERVICE AWARD:**
**Paul Lange, MD**

Awarded to a urologist whose actions at work or in the community exceed job expectations and reflect values of compassion, respect, trust, commitment to excellence and teamwork, and also educate the community about prostate cancer.

---

Facebook.com/UrologySUO  twitter.com/Uro_Onc
Educational Needs
Pathophysiology of the GU tract is complex. Treatment of GU malignancies has relied heavily on a single type of treatment administered at one time, followed by other modalities depending on treatment success. However, there is reason to believe multimodality therapy would have increased likelihood of efficacy. The goal of the meeting on is to address knowledge gaps and discuss the benefits and limitations of multimodality therapy for prostate, bladder and renal cancers.

Educational Objectives
At the conclusion of the SUO at the AUA 2019 Annual Meeting, attendees will be able to:

1.) Recognize the best multimodality systemic therapy advances for metastatic hormone-resistant prostate cancer.
2.) Explain the concept of oligometastatic treatment.
3.) Describe therapeutic advances in BCG-unresponsive non-muscle-invasive bladder cancer, including immune-based therapy, enhanced delivery systems and combination chemo-immune therapy.
4.) Discuss the best systemic therapy advances in metastatic kidney cancer.
5.) Describe the role of radical nephrectomy in the post-tyrosine kinase inhibitor era in renal cancer.
6.) Describe the impact of biological sex on manifestation of various lower urinary tract disorders including voiding dysfunction, infection and cancer.
7.) Explain the influence of resident microbes on urinary tract function and dysfunction, and the response to therapeutic intervention.

Educational Needs
The role of germline DNA testing is growing in many fields and its role in urologic oncology is becoming clearer, but best practices and ethical considerations may still not be fully appreciated. Many urologic oncology studies rely on large population databases, but the reader may not appreciate the pitfalls that these data can contain. Selecting surgical options for treatment of a small renal mass remains one of the major debates in kidney cancer despite prospective data, and case panelists will highlight the issues that may not be captured in such studies. Other controversies include the continued quest for an effective neoadjuvant and adjuvant treatment, with promising agents on the horizon.

For urothelial cancer, emerging data shows efficacy of gemcitabine, yet there is a need to clarify its role in comparison to the accepted standard of MMC. Similarly, there is a need to appreciate the potential incremental benefits of robotic cystectomy in view of ERAS which may provide greater generalizability to all practitioners. Many new molecular biomarker and imaging technologies are becoming available for prostate cancer. Clinicians who manage men with prostate cancer will need to know how to navigate the field as well as appropriate use and limitations of these new technologies.

Urologists need knowledge of how to reduce the overprescribing of opioids for patients following urologic procedures.

Educational Objectives
At the conclusion of the SUO at the AUA 2019 Annual Meeting, attendees will be able to:

1.) Identify appropriate at-risk patients for germline DNA testing and discuss ethical issues.
2.) Recognize the advantages and disadvantages of clinical studies using population based databases and particularly the limitations of data that may limit generalizability.
3.) Distinguish tumor, kidney, and patient factors favoring partial versus radical nephrectomy.
4.) List neoadjuvant and adjuvant studies and their impact on recurrence and survival of kidney cancer.
5.) Recommend options for treatment of advanced non-clear cell RCC.
6.) Identify the options for post-TUR intravesical therapy and their advantages and disadvantages.
7.) Diagnose BCG refractory disease and list options for salvage therapy.
8.) Explain the relative benefits of robotics and ERAS for cystectomy.
9.) Distinguish the different forms of prostate biopsy in the modern era.
10.) Explain the role of the urologist in preventing opiate addiction.
11.) Identify ideal patients for focal therapy.
12.) Compare imaging methods for evaluating patients with a rising PSA after local therapy.
13.) Describe circulating tumor factors in castration sensitive metastatic prostate cancer.
**SUO/SBUR Morning Joint Session Accreditation**

**Accreditation:** The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

**Credit Designation:** The American Urological Association designates this live activity for a maximum of 3.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

---

**SUO Afternoon Session AUA Accreditation**

**Accreditation:** The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

**Credit Designation:** The American Urological Association designates this live activity for a maximum of 4.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

---

**Other Learners:** The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

**Medical Ethics Designation:** The following presentations have been designated by the American Urological Association for a maximum totaling 0.50 credit of education in medical ethics and/or professional responsibility.

- Germline DNA Testing in Urology: Best Practices and Ethical Considerations
- Population Cancer Databases: Goldmines and Pitfalls for the Researcher, Reviewer and the Reader
- Opiate Use after Radical Prostatectomy: The End is Here

**Evidence Based Content:** It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

**AUA Disclosure Policy:** All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

**Resolution of Identified Conflict of Interest:** All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

- Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Conflict of Interest Review Work Group or its subgroup.
- Limit content to evidence with no recommendations
- Introduction of a debate format with an unbiased moderator (point-counterpoint)
- Inclusion of moderated panel discussion
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Limit equipment representatives to providing logistics and operation support only in procedural demonstration
- Divestiture of the relationship by faculty

**Off-label or Unapproved Use of Drugs or Devices:** The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

**AUA PARTICIPANT INFORMATION & POLICIES**

**Disclaimer:** The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

**Consent to Use of Photographic Images:** Attendance at or participation in AUA meetings and other activities constitutes an agreement by the registrant to AUA’s use and distribution (both now and in the future) of the attendee’s image or voice in photographs and electronic reproductions of such meetings and activities.

**Audio, Video and Photographic Equipment:** The use of audio, video and other photographic recording equipment by attendees is prohibited inside AUA meeting rooms.

**Reproduction Permission:** Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.

**Special Assistance/Dietary Needs:** The AUA complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary restrictions, please see the registration desk.

**Disclosure Report:** The disclosures for this meeting can be found at the following website: www.aua.org/speaker-central/disclosures
Kornelia Polyak, MD, PhD is a Professor of Medicine at Dana-Farber Cancer Institute, Harvard Medical School, and is an internationally recognized leader of the breast cancer field. Dr. Polyak received her MD in 1991 from Albert Szent-Gyorgyi Medical University, Szeged, Hungary, and her PhD in 1995 from Cornell University/Memorial Sloan-Kettering Cancer Center.

She completed a research fellowship in oncology at the Johns Hopkins Oncology Center, Baltimore, where she analyzed the mechanism of p53-mediated cell death. Joining DFCI in 1998, she is principally involved in basic laboratory research focusing on cancer genetics and the molecular basis of breast cancer.
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:40 p.m.</td>
<td>Urothelial Cancer</td>
<td></td>
</tr>
<tr>
<td>2:40 p.m.</td>
<td>Is Gemcitabine the New Post-TUR Standard of Care?</td>
<td>John L. Gore, MD, MS</td>
</tr>
<tr>
<td>2:48 p.m.</td>
<td>Rationale for Post-Ureteroscopy Intravesical Chemotherapy</td>
<td>Vitaly Margulis, MD</td>
</tr>
<tr>
<td>2:56 p.m.</td>
<td>BCG Refractory Disease: Three Cases, Three Experts</td>
<td>Trinity J. Bivalacqua, MD, PhD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sima P. Porten, MD, MPH</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Alexandre Zlotta, MD, PhD, FRCSC</td>
</tr>
<tr>
<td>3:11 p.m.</td>
<td>ERAS vs. Robotics: Which Provides the Most Incremental Benefit?</td>
<td></td>
</tr>
<tr>
<td>3:11 p.m.</td>
<td>ERAS</td>
<td>Siamak Daneshmand, MD</td>
</tr>
<tr>
<td>3:19 p.m.</td>
<td>Robotic Surgery</td>
<td>Dipen J. Parekh, MD</td>
</tr>
<tr>
<td>3:27 p.m.</td>
<td>Instiladrin Late-Breaking Phase 2 Data</td>
<td>Colin Dinney, MD</td>
</tr>
<tr>
<td>3:33 p.m.</td>
<td>Three Papers in the Past Year that Influenced My Practice</td>
<td></td>
</tr>
<tr>
<td>3:41 p.m.</td>
<td>Discussion/Q&amp;A</td>
<td>Angela B. Smith, MD, MS</td>
</tr>
<tr>
<td>3:55 p.m.</td>
<td>Prostate Cancer</td>
<td></td>
</tr>
<tr>
<td>3:55 p.m.</td>
<td>What Kind of Biopsy Should I Be Doing?</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Three Cases, Three Experts</td>
<td>Mark Emberton, MD, FACS</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Jeffrey M. Holzbeilerlein, MD, FACS</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Daniel W. Lin, MD</td>
</tr>
<tr>
<td>4:10 p.m.</td>
<td>Opiate Use After Radical Prostatectomy: The End is Here</td>
<td>Benjamin Davies, MD</td>
</tr>
<tr>
<td>4:17 p.m.</td>
<td>Who Should We Consider For Focal Therapy and How?</td>
<td>Ardeshir R. Rastinehad, DO, FACOS</td>
</tr>
<tr>
<td>4:25 p.m.</td>
<td>Rising PSA After Local Therapy: New Imaging for Recurrent Prostate Cancer</td>
<td>Peter Carroll, MD</td>
</tr>
<tr>
<td>4:33 p.m.</td>
<td>Circulating Tumor Factors in Castration Sensitive Metastatic Prostate Cancer</td>
<td>Amir Goldkorn, MD</td>
</tr>
<tr>
<td>4:41 p.m.</td>
<td>Three Papers in the Past Year that Influenced My Practice</td>
<td>Brian F. Chapin, MD</td>
</tr>
<tr>
<td>4:49 p.m.</td>
<td>Discussion/Q&amp;A</td>
<td></td>
</tr>
</tbody>
</table>
The Society of Urologic Oncology and European Association of Urology partnered to create an exchange program for young urologic oncologists.

This program provides an opportunity for urologic oncologists within eight years of completing fellowship training to apply for a two week scholarly visit to an institution in Europe. Exchange scholars will expand their knowledge in global urologic healthcare and facilitate collaboration between members of both organizations.

The SUO will sponsor one Y.U.O. member per year to visit a European institution to learn a new technique, technology, or method in clinical practice, translational research, or basic research science. The visit will last two weeks and coincide with the Annual EAU Congress in March. The exchange scholar will receive complimentary registration to attend the Congress.

In return, a SUO member will host a young urologic oncologist from the EAU at his or her institution for two weeks in December, allowing the young urologic oncologist to attend the SUO Annual Meeting.

Applications will be begin to be accepted during the summer, and will be due on October 15.

---

**INFORMATION AND QUALIFICATIONS**

Young urologic oncologists interested in applying for the exchange program must meet and adhere to the following criteria:

1. The applicant must submit all material by **October 15**. (The deadline will not change from year to year.)
2. The applicant must submit a copy of his or her CV with other application material.
3. The applicant must be within eight years of completing fellowship training.
4. The applicant must work out the details of the exchange and gain commitment from a host prior to submitting this application. See the SUO website for more information on host requirements.
5. The applicant must be a member of the Young Urologic Oncologists Section of the SUO. For more information about Y.U.O., visit SUOnet.org.
6. The applicant must submit a two page proposal detailing an unmet educational need and how the applicant will implement the new knowledge upon return from the exchange.
7. The applicant will file a two page report with the SUO within one month of returning from the exchange program.

The SUO and EAU will waive the meeting registration for exchange scholars. The SUO will provide a travel stipend of up to $7,500 to its US or Canadian exchange scholar. That sums includes an estimated $2,000 in airfare, $4,725 in room and board, and $775 for miscellaneous items such as taxi fares.

Applications are due **October 15**. The proposals will be reviewed by a joint committee at the SUO comprised of Y.U.O. and Executive Committee members. A finalist will be selected and announced at the SUO Annual Meeting.
Thank You to Our 2018 Promotional Partners

Platinum Level Partners

MERCK

Silver Level Partners

astellas  Pfizer  Oncology  AstraZeneca  MedImmune  UroGen Pharma

Thank You to Our 2019 Contributor

Genomic Health

SAVE THE DATE

20th Annual Meeting of the Society of Urologic Oncology

December 4 – 6, 2019
Renaissance Washington DC

Register quickly and easily at: suonet.org/register

ABSTRACTS DEADLINE: AUGUST 2019